Clinical Trial

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Protocol Amendment History 59 amendments
This ClinicalTrials.gov record has been amended 59 times since 2021-03-08; most recent amendment 2026-07-22.
Status change: Recruiting → Active, Not Recruiting 2024-01-04
Status change: Not Yet Recruiting → Recruiting 2021-03-17
Trial Details
NCT Number NCT04793958
Lead Sponsor Mirati Therapeutics Inc.
Conditions Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Enrollment 461 participants
Start Date 2021-06-24
Primary Completion 2026-01-16 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-23